Hepatitis C

Recognizing Hepatitis R&D on World Hepatitis Day

Hepatitis is an inflammation of the liver, most commonly caused by a viral infection. There are five main hepatitis viruses, with types A, B, C most common. In 2018, the Centers for Disease Control and Prevention estimated that Americans were infected with 24,900 cases of hepatitis A and 21,600 cases of hepatitis B, many of …

Recognizing Hepatitis R&D on World Hepatitis Day Read More »

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well?

Hepatitis is an infection that causes inflammation of the liver. The condition can be self-limiting or can progress to fibrosis (scarring), cirrhosis, or liver cancer. Hepatitis viruses are the most common cause of hepatitis; however, other infections such as toxic substances (e.g., alcohol, certain drugs) and autoimmune diseases can also cause hepatitis. The hepatitis viruses …

Evolution in Hepatitis B and C Virus: Can we expect success similar to Hepatitis C in Hepatitis B as well? Read More »

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisition

Gilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – but revenues are declining as the pandemic bit into sales of its hepatitis C drugs. Product sales in Q2 were down nearly 10% compared with last year to just over $5 billion, and the company recorded a …

Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisition Read More »

The need for continuous cost-effectiveness analysis

At drug launch, treatments have some benefit and cost. However, drug prices may change over time. Additionally, treatment benefits may rise or fall depending on how well efficacy translates into effectiveness and how well physicians learn to manage adverse events. Mattingly and Love (2020) provide a case study of how cost-effectiveness analysis can change over …

The need for continuous cost-effectiveness analysis Read More »